Recruiting
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM - NDS-MM-004
Updated: 24 March, 2021 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
Inclusion Criteria: - Patient is ≥ 18 years old with a diagnosis of Multiple Myeloma - Patient must reside in the USA. - Patients within each of the following subgroups, at one of the following timepoints, will be eligible for entry: 1. Newly-diagnosed multiple myeloma transplant-eligible 2. Patients undergoing their first ASCT 3. Newly-diagnosed multiple myeloma transplant-ineligible 4. Relapsed and/or refractory. Exclusion Criteria: - Patient has a condition(s) that, in the opinion of the Investigator, would make participation infeasible such as inability to provide informed consent, illiteracy, or inability to speak, read, and write in English. - Patient is on hospice. - Patient is receiving or has received an investigational agent < 28 days prior to randomization or during this pilot study.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
